| Name | Title | Contact Details |
|---|---|---|
Kim Warren |
Chief Technology Officer | Profile |
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
InMed Diagnostics is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Du Pont Pharmaceuticals Co is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Highline Sciences is a specialized, full-service CRO and consultancy founded from within an oncology biotech to provide a better solution. We understand the gap between what you need and what you get from a traditional CRO and we’re here to improve the...
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.